Novel protein kinase inhibitors: SMART drug design technology

BioTechniques

Volumn 34, Issue 6 SUPPL., 2003, Pages

  Sawyer, Tomi K ^a   Bohacek, Regine S ^a   Metcalf III, Chester A ^a   Shakespeare, William C ^a   Wang, Yihan ^a   Sundaramoorthi, Raji ^a   Keenan, Terence ^a   Narula, Surinder ^a   Weigele, Manfred ^a   Dalgarno, David C ^a  

^a ARIAD PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; C TERMINAL SRC KINASE; COLONY STIMULATING FACTOR RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; HEMATOPOIETIC CELL KINASE; I KAPPA B; INSULIN RECEPTOR; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; NERVE GROWTH FACTOR RECEPTOR; PHOSPHOINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN KINASE FYN; PROTEIN KINASE INHIBITOR; PROTEIN KINASE LCK; PROTEIN KINASE P60; PROTEIN TYROSINE KINASE; SOMATOMEDIN RECEPTOR; TRANSFORMING GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; ENZYME INHIBITOR;

DRUG DESIGN; DRUG TARGETING; ENZYME INHIBITION; ENZYME SPECIFICITY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN STRUCTURE; REVIEW; SMART DRUG DESIGN TECHNOLOGY; X RAY ANALYSIS; CHEMICAL STRUCTURE; DRUG DELIVERY SYSTEM; HUMAN; PROTEIN CONFORMATION;

JANUS;

DRUG DELIVERY SYSTEMS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS;

EID: 0642367580     PISSN: 07366205     EISSN: None     Source Type: Journal    
DOI: 10.2144/sawyerjun03revised     Document Type: Review

References (98)

1. Sawyer, T., B. Boyce, D. Dalgarno, and J. Iuliucci. 2001. Src inhibitors: genomics to therapeutics. Expert Opin. Investig. Drugs 10:1327-1344.
2. Frame, M.C. 2002. Src in cancer: deregulation and consequences for cell behaviour. Biochim. Biophys. Acta 1602:114-130.
3. Sawyer, T.K. Cancer metastasis: therapeutic targets and drug discovery. Expert Opin. Investig. Drugs (In press).
4. McMahon, G., L. Sun, C. Liang, and C. Tang. 1998. Protein kinase inhibitors: structural determinants for target specificity. Curr. Opin. Drug Discov. Devel. 1:131-146.
5. Strawn, L.M. and L.K. Shawver. 1998. Tyrosine kinases in diseases. Overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials. Exp. Opin. Invest. Drugs 7:533-573.
6. Traxler, P. 1998. Tyrosine kinase inhibitors in cancer treatment (part II). Exp. Opin. Ther. Patents 8:1599-1628.
7. Lawrence, D.S. and J. Niu. 1998. Protein kinase inhibitors: the tyrosine-specific kinases. Pharmacol. Ther. 77:81-114.
8. Bridges, A.J. 1999. The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases. Curr. Med. Chem. 6:825-843.
9. Toledo, L.M., N.B. Lydon, and D. Elbaum. 1999. The structure-based design of ATP-site directed protein kinases. Curr. Med. Chem. 6:775-805.
10. Stover, D.R., N.B. Lydon, and J.J. Nunes. 1999. Recent advances in protein kinase inhibition: current molecular scaffolds used for inhibitor synthesis. Curr. Opin. Drug Discov. Devel. 2:274-285.
11. Sedlacek, H.H. 2000. Kinase inhibitors in cancer therapy. Drugs 59:435-476.
12. Tsatsanis, C. and D.A. Spanidos. 2000. The role of oncogenic kinases in human cancer. Int. J. Mol. Med. 5:583-590.
13. Dalgarno, D.C., C.A. Metcalf, W.C. Shakespeare, and T.K. Sawyer. 2000. Signal transduction drug discovery: targets, mechanisms, and structure-based design. Curr. Opin. Drug Discov. Devel. 3:549-564.
14. Dumas, J. 2001. Protein kinase inhibitors: emerging pharmacophores 1997-2000. Exp. Opin. Ther. Patents 11:405-429.
15. Fabbro, D., S. Ruetz, E. Buchdunger, S.W. Cowan-Jacob, G. Fendrich, J. Liebetanz, et al. 2002. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol. Ther. 93:79-98.
16. Cohen, P. 2002. Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1:309-315.
17. Brunelleschi, S., L. Penesgo, M.M. Santoro, and G. Gaudino. 2002. Receptor tyrosine kinases as target for anti-cancer therapy. Curr. Pharm. Des. 8:1959-1972.
18. Drevs, J., M. Medinger, C. Schmidt-Gersbach, R. Weber, and C. Unger. 2003. Receptor tyrosine kinases: the main targets for new anticancer therapy. Cur. Drug Targets 4:113-121.
19. Metcalf, C.A., III, M.R. van Schravendijk, D.C. Dalgarno, and T.K. Sawyer. 2002. Targeting protein kinases for bone disease: discovery and development of Src inhibitors. Curr. Pharm. Des. 8:2049-2075.
20. Dancey, J. and E.A. Sausville. 2003. Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Discov. 2:296-313.
21. International Human Genome Consortium. 2001. Initial sequencing and analysis of the human genome. Nature 409:860-921.
22. Venter, J.C., M.D. Adams, E.W. Myers, P.W. Li, et al. 2001. The sequence of the human genome. Science 291:1304-1351.
23. Manning G., D.B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam. 2002. The protein kinase complement of the human genome. Science 298:1912-1934.
24. Peggs K. and S. Mackinnon. 2003. Imatinib mesylate - the new gold standard for treatment of chronic myeloid leukemia. N. Engl. J. Med. 348:1048-1050.
25. Druker, B.J. 2003. Imatinib alone and in combination for chronic myeloid leukemia. Semin. Hematol. 40:50-58.
26. Ottmann, O.G., B. Wassmann, and D. Hoelzer. 2002. Imatinib for relapsed BCR/ABL positive leukemias. Ann. Hematol. 81(Supp12):S36-S37.
27. Wakeling, A.E., S.P. Guy, J.R. Woodburn, S.E. Ashton, B.J. Curry, A.J. Barker, and ICH. Gibson. 2002. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 62:49-54.
28. Wakeling, A.E. 2002. Epidermal growth factor receptor tyrosine kinase inhibitors. Curr. Opin. Pharmacol. 2:382-387.
29. Ranson, M., W. Mansoor, and G. Jayson. 2002. ZD 1839 (IRESSA): a selective EGFR-TK inhibitor. Expert Rev. Anticancer Ther. 2:161-168.
30. Thomas, S.M. and J.S. Brugge. 1997. Cellular functions regulated by Src family kinases. Annu. Rev. Cell. Dev. Biol. 13:513-609.
31. Biscardi, J.S., D.A. Tice, and S.J. Parsons. 1999. c-Src, receptor tyrosine kinases, and human cancer. Adv. Cancer Res. 76:61-119.
32. Susa, M., M. Missbach, and J. Green. 2000. Src inhibitors: drugs for the treatment of osteoporosis, cancer or both? Trends Pharmacol. Sci. 21:489-495.
33. Susa, M. and A. Teti. 2000. Tyrosine kinase Src inhibitors: potential therapeutic applications. Drug News Perspect. 13:169-175.
34. Soriano, P., C. Montgomery, R. Geske, and A. Bradley. 1991. Targeted disruption of the c-Src proto-oncogene leads to osteopetrosis in mice. Cell 64:693-702.
35. Lowe, C., T. Yoneda, B.F. Boyce, H. Chen, et al. 1993. Osteopetrosis in Srcdeficient mice is due to an autonomous defect of osteoclasts. Proc. Natl. Acad. Sci. USA 90:4485-4489.
36. Schwartzberg, P.L., L. Xing, O. Hoffmann, et al. 1997. Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-/- mutant mice. Genes Dev. 11:2835-2844.
37. Marzia, M., N.A. Sims, S. Voit, S. Migliacco, et al. 2000. Decreased c-Src expression enhances osteoblast differentiation and bone formation. J. Cell Biol. 151:311-320.
38. Amling, M., I. Neff, M. Priemel, A.F. Schilling, et al. 2000. Progressive increase in bone mass and development of odontomas in aging osteopetrotic csrc-deficient mice. Bone 27:603-610.
39. Lowell, C.A. and P. Soriano. 1996. Knockouts of Src-family kinases: stiff bones, wimpy T cells, and bad memories. Genes Dev. 10:1845-1857.
40. Benistant, C., J.-F. Bourgaux, H. Chapuis, N. Mottet, et al. 2001. The COOH-terminal Src kinase Csk is a tumor antigen in human carcinoma. Cancer Res. 61:1415-1420.
41. Bjorge, J.D., A. Pang, and D.J. Fujita. 2000. Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines. J. Biol. Chem. 275:41439-41446.
42. Wilson, L.K., D.K. Luttrell, J.T. Parsons, and S.J. Parsons. 1989. pp60c-src tyrosine kinase, myristylation, and modulatory domains are required for enhanced mitogenic responsiveness to epidermal growth factor seen in cells overexpressing c-Src. Mol. Cell. Biol. 9:1536-1544.
43. Maa, M.-C., T.H. Leu, D.J. McCarley, R.C. Schatzman, and S.J. Parsons. 1995. Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. Proc. Natl. Acad. Sci. USA 92:6981-6985.
44. Mao, W., R. Irby, D. Coppola, L. Fu, et al. 1997. Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene 15:3083-3090.
45. Turkson, J., T Bowman, R. Garci, E. Caldenhove, et al. 1998. STAT3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell. Biol. 18:2545-2552.
46. Staley, C.A., N.U. Parikh, and G.E. Gallick. 1997. Decreased tumorigenicity of a human colon carcinoma cell line by an antisense expression vector specific for c-Src. Cell Growth Differ. 8:269-274.
47. Ellis, L.M., C.A. Staley, W. Liu, R.Y. Fleming, et al. 1998. Downregulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-Src. J. Biol. Chem. 273:1052-1057.
48. Irby, R.B., W. Mao, D. Coppola, J. Kang, et al. 1999. Activating SRC mutation in a subset of advanced human colon cancers. Nat. Genet. 21:187-190.
49. Egan, C., A. Pang, D. Durda, H.-C. Cheng, et al. 1999. Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530. Oncogene 18:1227-1237.
50. Verbeek, B.S., T.M. Vroom, S.S. Adriaansen-Slot, A.E. Ottenhoff-Kalif, et al. 1996. c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J. Pathol. 180:383-388.
51. Talamonti, M.S., M.S. Roh, S.A. Curley, and G.E. Gallick. 1993. Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J. Clin. Invest. 91:3-60.
52. Van Oijen, M.G., C.T. Rijkseng, F.W. ten Broek, and P.J. Slootweg. 1998. Overexpression of c-Src in areas of hyperproliferation in head and neck cancer, premalignant lesions and benign mucosal disorders. J. Oral Pathol. Med. 27:147-152.
53. Lutz, M.P., I.B. Esser, B.B. Flossmann-Kast, R. Vogelmann, et al. 1998. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem. Biophys. Res. Commun. 243:503-508.
54. Cohen, G.B., R. Ren, and D. Baltimore. 1995. Modular binding domains in signal transduction. Cell 80.237-248.
55. Pawson, T. 1995. Protein modules and signalling networks. Nature 373:573-580
56. Dalgarno, D.C., M.C. Botfield, and R.J. Rickles. 1997. SH3 domains and drug design: ligands, structure, and biological function. Biopolymers (Peptide Sci.) 43:383-400.
57. Sawyer, T.K., R.S. Bohacek, D.C. Dalgarno, C.J. Eyermann, N. Kawahata, C.A. Metcalf, III, et al. 2002. SRC homology-2 inhibitors: peptidomimetic and nonpeptide. Mini Rev. Med. Chem. 2:475-488.
58. Xu, W., A. Doshi, M. Lei, M. Eck, and S.C. Harrison. 1999. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol. Cell 3:629-636.
59. Zhu, X., J.L. Kim, J.R. Newcomb, P.E. Rose, D.R. Stover, et al. 1999. Structural analysis of the lymphocyte-specific Lck in complex with non-selective and Src family-selective kinase inhibitors. Structure 7:651-661.
60. Schindler, T., F. Sichieri, A. Pico, A. Gazit, et al. 1999. Crystal structure of Hck in complex with Src family-selective tyrosine kinase inhibitor. Mol. Cell 3:639-648.
61. Lamers, M.B., A.A. Antson, R.E. Hubbard, R.K. Scott, and D.H. Williams. 1999. Structure of C-terminal Src kinase (CSK) in complex with staurosporine. J. Mol. Biol. 28:713-725.
62. Hubbard, S.R. 1997. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. 16:5572-5581.
63. Mohammadi, M., G. McMahon, L. Sun, PC. Tang, et al. 1997. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 276:955-960.
64. McTigue, M.A., J.A. Wilkersham, C. Pinko, R.E. Showalter, et al. 1999. Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis. Structure Fold. Des. 7:319-330.
65. Gray, N.S., L. Wodicka, A.-M. Thunnissen, T.C. Norman, S. Kwon, et al. 1998. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281:533-538.
66. Legravend, M., P. Tunnah, M. Noble, P. Ducrot, et al. 2002. Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex. J. Med. Chem. 43:1282-1292.
67. Dreyer, M.K., D.R. Borcherding, J.A. Dumont, N.P. Peet, et al. 2001. Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717. J. Med. Chem. 44:524-530.
68. Schindler, T., W. Bommann, P. Pellicena, W.T. Miller, et al. 2002. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289:1938-1942.
69. Shah, K., Y. Liu, C. Deirmengian, and K.M. Shokat. 1997. Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label is direct substrates. Proc. Natl. Acad. Sci. USA 94:3565-3570.
70. Bishop, A.C., K. Shah, Y. Liu, L Witucki, et al. 1998. Design of allele-specific inhibitors to probe protein kinase signaling. Curr. Biol. 8:257-266.
71. Bishop, A.C., C.-Y. Kung, K. Shah, L. Witucki, et al. 1999. Generation of monospecific nanomolar tyrosine kinase inhibitors via a chemical genomics approach. J. Am. Chem. Soc. 121:627-631.
72. Tong, L., S. Pav, D.M. White, S. Rogers, K.M. Crane, C.L. Cywin, M.L. Brown, and C.A. Pargellis. 1997. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nat. Struct. Biol. 4:311-316.
73. Chen, J. and Y. Fang. 2002. A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling. Biochem. Pharmacol. 64:1071-1077.
74. Huang, S. and P.J. Houghton. 2002. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr. Opin. Investig. Drugs 3:295-304.
75. Missbach, M., E. Attman, and M. Susa. 2000. Tyrosine kinase inhibition in bone metabolism. Curr. Opin. Drug Discov. 3:541-548
76. Metcalf, C., III, Y. Wang, W. Shakespeare, R. Sundaramoorthi, T. Keenan, D. Dalgarno, et al. 2003. Discovery of potent and selective Src inhibitors and their development as antitumor and antimetastatic agents. Proc. AACR 44:A1716.
77. Hanke, J.H., J.P. Gardner, R.L. Dow, P.S. Changelian, et al. 1996. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. J. Biol. Chem. 271:695-701.
78. Missbach, M., M. Jeschke, J. Feyer, K. Muller, et al. 1999. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone 24:437-449.
79. Kneissel, M., R. Gamse, M. Missbach, L. Wilder, et al. 1999. Tyrosine kinase Src inhibitor CGP 76030 suppresses rapid bone loss induced by retinoic acid in rats. Calcif. Tissue Int. 64(Suppl 1):S75.
80. Hamby, J.M., C.J.C. Connolly, M.C. Schroeder, R.T. Winters, et al. 1997. Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J. Med. Chem. 40.2296-2303.
81. Batley, B.L., A.M. Doherty, J.M. Hamby, G.H. Lu, P. Keller, T.K. Dahring, O. Hwang, K. Crickard, and R.L. Panek. 1998. Inhibition of FGF-1 receptor tyrosine kinase activity by PD 161570, a new protein-tyrosine kinase inhibitor. Life Sci. 62:143-150.
82. Kraker, A.J., B.G. Hartl, A.M. Amar, M.R. Barvian, et al. 2000. Biochemical and cellular effects of c-Src kinase-selective pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. Biochem. Pharmacol. 60:885-898.
83. Wang, Y.D., K. Miller, D.H. Boschelli, F. Ye, et al. 2000. Inhibitors of Src tyrosine kinase: the preparation and structure-activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines. Bioorg. Med. Chem. Lett. 10:2477-2480.
84. Boschelli, D.H., Y.D. Wang, F. Ye, B. Wu, et al. 2001. Synthesis and Src kinase inhibitory activity of a series of 4-phenylamino-3-quinolinecarbonitriles. J. Med. Chem. 44:822-833.
85. Blake, R.A., M.A. Broome, X. Liu, J. Wu, et al. 2000. SU6656, a selective Src family kinase inhibitor used to probe growth factor signaling. Mol. Cell. Biol. 20:9018-9027.
86. Zimmerman, J., E. Buchdunger, H. Mett, T. Meyer, and N.B. Lydon. 1997. Potent and selective inhibitors of the Abl-kinase: phenylaminopyrimidine (PAP) derivatives. Bioorg. Med. Chem. Lett. 7:187-192.
87. Yoneda, T., C. Lowe, C.-H. Lee, G. Gutierra, et al. 1993. Herbimycin A, a pp60c-src tyrosine kinase inhibitor, inhibits osteoclastic bone resorption in vitro and hypercalcemia in vivo. J. Clin. Invest. 91:2791-2795.
88. Maly, D.J., I.C. Choong, and J.A. Ellman. 2000. Combinatorial target-guided ligand assembly: identification of potent subtype-selective c-Src inhibitors. Proc. Natl. Acad. Sci. USA 97:2419-2424.
89. Alfaro-Lopez, J., W. Yuan, B.C. Phan, J. Kamath, et al. 1998. Discovery of a novel series of potent and selective substrate-based inhibitors of pp60c-src protein tyrosine kinase: conformational and topographical constraints in peptide design. J. Med. Chem. 41:2252-2260.
90. Shakespeare, W., Y. Wang, C. Metcalf, R. Sundaramoorthi, T. Keenan, R. Bohacek, et al. 2003. Development of a novel bone-targeted Src tyrosine kinase inhibitor AP23451 having potent activity in an animal model of osteolytic bone metastasis. Proc. AACR 44:A3871.
91. Feng, S., T.M. Kapoor, F. Shirai, A.P. Combs, and S.L. Schreiber. 1996. Molecular basis for the binding of SH3 ligands with non-peptide elements identified by combinatorial synthesis. Chem. Biol. 3:661-670.
92. Shakespeare, W.C., M. Yang, R. Bohacek, F. Cerasoli, et al. 2000. Structurebased design of an osteoclast-selective, nonpeptide Src homology 2 inhibitor with in vivo antiresorptive activity. Proc. Natl. Acad. Sci. USA 97:9373-9378.
93. Shakespeare, W.C., R.S. Bohacek, M.D. Azimiora, K.J. Macek, et al. 2000. Structure-based design of novel bicyclic inhibitors for the Src SH2 domain. J. Med. Chem. 43:3815-3819.
94. Bohacek, R.S., D.C. Dalgarno, M. Hatada, V.A. Jacobsen, et al. 2001. X-ray structure of citrate bound to Src SH2 leads to high-affinity, bone-targeted Src SH2 inhibitor. J. Med. Chem. 44:660-663.
95. Wang, Y., C.A. Metcalf III, W.C. Shakespeare, R. Sundaramoorthi, T.P. Keenan, R.S. Bohacek, et al. Bone-targeted 2,6,9-trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseases. Bioorg. Med. Chem. Lett. (In press).
96. Sundaramoorthi, R., W.C. Shakespeare, T.P. Keenan, C.A. Metcalf III, Y. Wang, U. Mani, et al. Bone-targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analogs. Bioorg. Med. Chem. Lett. (In press).
97. Vu, C., G.P. Luke, N. Kawahata, W.C. Shakespeare, Y. Wang, R. Sundaramoorthi, et al. Bone-targeted pyrido[2,3-d]pyrimidin-7-ones: potent inhibitors of Src tyrosine kinase as novel antiresorptive agents. Bioorg. Med. Chem. Lett. (In press).
98. Sawyer, T.K. 2002. Smart chemistry tackling complex biology. Targets: Innovations Genomics Proteomics 1:81-82.